Fenbendazole for Cancer

Medically Reviewed By Dr. Imran Khan, MD, IFMCP

Last Updated: September 12, 2026

Why Fenbendazole Has Gained Attention in Cancer Care

Fenbendazole has gained attention among people exploring additional options during cancer care, largely through online discussions, laboratory research, and personal stories.

While early research has raised scientific interest, evidence in humans remains limited. Understanding the difference between preclinical findings, personal experiences, and established clinical evidence is important when evaluating claims about fenbendazole.

Medical Disclaimer: This article is for educational purposes only and is not medical advice or a treatment protocol. Fenbendazole is not FDA-approved for human use or cancer treatment. Always discuss unapproved or complementary approaches with your treating oncologist.

What Is Fenbendazole?

Fenbendazole belongs to a class of antiparasitic drugs called benzimidazole anthelmintics. Some related drugs, including mebendazole and albendazole, have approved uses in people and have separately been investigated in cancer research. However, evidence involving those medications should not be treated as evidence that fenbendazole is safe or effective in humans. Fenbendazole itself has not been approved by the FDA for human use for any purpose, including cancer treatment.

A 2024 review published in Anticancer Research identified several barriers to evaluating fenbendazole in people, including poor oral absorption, rapid metabolism by the liver, unclear human dosing, and insufficiently documented human pharmacokinetics and safety. Further clinical research would be necessary to determine whether it could be studied safely or effectively in people.

Important research note: A 2025 case series involving three patients who self-administered fenbendazole was retracted by the publisher and journal editor in January 2026. The retraction followed concerns about a potential undeclared conflict of interest that the editor concluded could have affected the interpretation of the work and its recommendations. The retracted article should not be used as evidence that fenbendazole is effective against cancer.

Who Is Joe Tippens and What Is the Joe Tippens Protocol?

Joe Tippens is a cancer patient whose widely shared personal story helped increase public interest in fenbendazole. He reported taking veterinary fenbendazole and other substances while also participating in a clinical study involving an FDA-approved immunotherapy for his type of lung cancer. Because several interventions occurred during the same period, his experience cannot establish that fenbendazole caused his reported outcome.

His approach became known online as the Joe Tippens Protocol, but it remains an anecdotal account rather than controlled clinical evidence. There is no clinically established fenbendazole protocol for treating cancer in humans.

What Does Research Show About Fenbendazole and Cancer?

A 2018 study published in Scientific Reports examined several ways fenbendazole affected cancer cells under experimental conditions.

These findings came from preclinical models and do not establish effectiveness in humans.

A 2025 study found that fenbendazole reduced cancer-cell proliferation and increased apoptosis in cervical cancer models. The study also reported suppressed tumor growth in animal models and examined effects involving cancer stem cells.

Together, these studies help explain the scientific interest in fenbendazole. However, they only identify laboratory mechanisms that may warrant further investigation. They do not establish that fenbendazole is safe or effective or that it improves tumor response, survival, quality of life, or any other clinical outcome in people with cancer.

Is Fenbendazole Safe for Humans?

Fenbendazole’s use in animals does not establish its safety in people. Questions about human safety, dosing, treatment schedules, and tolerability remain unresolved.

Published case reports have described liver inflammation and drug-induced liver injury in people who self-administered fenbendazole. These reports cannot show how frequently such reactions occur, but they demonstrate that self-administration is not risk-free.

Potential interactions with chemotherapy, immunotherapy, targeted therapy, radiation-related medications, and other drugs also remain uncertain. Patients should not self-administer veterinary fenbendazole or follow dosing protocols found online. Anyone already taking fenbendazole should tell their treating oncologist so that potential adverse effects, interactions, and changes in laboratory results can be evaluated.

What Are the Limits of Fenbendazole Research?

Important questions remain about fenbendazole as a potential cancer treatment:

Answering these questions requires well-designed human clinical studies. Until stronger evidence is available, fenbendazole remains an experimental area of cancer research, not an established cancer treatment.

Other Emerging Approaches Patients May Encounter

Patients researching fenbendazole may also encounter other compounds discussed in relation to cancer care, including artemisinin. These compounds have their own research, safety considerations, and evidence limitations. Read our Artemisinin for Cancer research guide to learn more about the current research.

At IHAWMD, we help patients review emerging research in the context of their current care. Our personalized cancer care supports informed discussions with each patient’s licensed oncology team and does not replace standard cancer treatment.

Medical Disclaimer: This article is for educational purposes only and is not medical advice or a treatment protocol. Fenbendazole is not FDA-approved for human use or cancer treatment. Always discuss unapproved or complementary approaches with your treating oncologist.

Discuss Emerging Cancer Research With Your Care Team

If you have questions about fenbendazole or other emerging approaches, schedule a consultation with IHAWMD. Our medical team can help you review the available evidence and prepare informed questions for your licensed oncology team. IHAWMD does not recommend self-administering veterinary fenbendazole or replacing established cancer treatment with an unapproved approach.